- Home
- HR vs PCVX Comparison
HR vs PCVX Comparison
Compare HR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HR | PCVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HR | PCVX |
|---|---|---|
| Price | $17.25 | $46.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $19.57 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 02-18-2026 | 02-24-2026 |
| Dividend Yield | ★ 5.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,204,680,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.09 | $27.66 |
| 52 Week High | $18.97 | $93.77 |
Technical Indicators
Market Signals| Indicator | HR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 52.91 |
| Support Level | $17.04 | $44.57 |
| Resistance Level | $17.42 | $49.55 |
| Average True Range (ATR) | 0.29 | 2.13 |
| MACD | 0.06 | 0.15 |
| Stochastic Oscillator | 69.28 | 52.90 |
Price Performance
Historical ComparisonAbout HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.